Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt

Drug Abuse: early-phase trial registry

3 of 22 indexed Drug Abuse trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 3 currently recruiting · #756 of 28,707 conditions by registered trial count

Drug Abuse: 22 US clinical trials tracked, 3 recruiting.

Drug Abuse is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is T. John Winhusen, PhD, running 3 of these trials.

Enrollment posture brief

Registry condition drug-abuse

OPEN 3 | RECR 14% | LATE 3 | EARLY 7 | RANK #756 | SPON 3

Nearest open-share peer: Chronic Myeloproliferative Disorders (14% recruiting · 22 trials)

Advanced Melanoma63.6%Acute Myeloid Leukemia Arisi18.2%Drug Abuse (this)14%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Drug Abuse

Drug Abuse lists 3 open slots (14% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Drug Abuse on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Drug Abuse is recruiting below its size-band peers.

    3 of 22 indexed trials (13.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Drug Abuse trials is spread across many organizations.

    T. John Winhusen, PhD accounts for 3 of 22 trials (13.6%). 18 distinct sponsors appear on at least one study for this condition label.

  3. Typical Drug Abuse enrolment sits around 130 participants.

    Median target enrolment is 130 among the 22 trials that report a genuine target (sentinel values excluded). 8 of those (36.4%) plan for fewer than 100 participants.

  4. Drug Abuse research is mostly interventional.

    19 interventional and 3 observational studies make up this index (86.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 22Phase 32Phase 41

Open and recent trials

22 total, page 1 of 1

RECRUITING NA 1,000 participants

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

National Institute on Drug Abuse (NIDA)

NCT01036581

RECRUITING NA 176 participants

Wakaya: Rising Up for Choctaw Youth Health

University of Washington

NCT05818384

RECRUITING NA 130 participants

Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Emory University

NCT02604277

ACTIVE NOT RECRUITING NA 250 participants

OUD Smartphone Services

Western Michigan University

NCT06134882

COMPLETED NA 1,285 participants

Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments

University of New Mexi

NCT01207791

COMPLETED NA 1,228 participants

Adolescent Family-Based Alcohol Prevention

Pacific Institute for Research and Evaluation

NCT00858065

COMPLETED Phase 3 589 participants

Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use

Boston Medical Center

NCT00876941

COMPLETED Phase 2 500 participants

Indirect Assessment and Intervention for Perinatal Drug Use

Wayne State University

NCT01650675

COMPLETED Phase 1 442 participants

Acute Intervention to Reduce Distress Following Sexual Assault

Medical University of South Carolina

NCT01622855

COMPLETED Phase 2 296 participants

Youth Drug Abuse Family and Cognitive-Behavioral Therapy

University of Florida

NCT00198874

COMPLETED Phase 3 140 participants

Medication Treatment for Opioid Use Disorder in Expectant Mothers

T. John Winhusen, PhD

NCT03918850

COMPLETED 128 participants

Effects of Nicotine on Brain Activity as Measured by fMRI

National Institute on Drug Abuse (NIDA)

NCT01037153

COMPLETED Phase 1 121 participants

Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use

Boston Children's Hospital

NCT00907309

COMPLETED NA 100 participants

Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention

University of Michigan

NCT03368456

COMPLETED 97 participants

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

T. John Winhusen, PhD

NCT03911466

COMPLETED NA 80 participants

Computerized Brief Intervention vs. Delayed Computerized Brief Intervention

Friends Research Institute

NCT01936623

COMPLETED 71 participants

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

T. John Winhusen, PhD

NCT03911739

COMPLETED Phase 4 60 participants

Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

Yale University

NCT00798538

COMPLETED NA 46 participants

Effects of Levetiracetam (Keppra) on Alcohol Consumption

University of California, San Francisco

NCT01168687

COMPLETED Phase 1 42 participants

A Study to Evaluate Abuse Potential of Istradefylline

Kyowa Kirin Co.

NCT02609477

COMPLETED Phase 1 40 participants

Disulfiram Interactions With HIV Medications: Clinical Implications

University of California, San Francisco

NCT00878306

COMPLETED Phase 1 19 participants

Evaluation of Smoked THC and CBD in Men and Women

University of California, Los Angeles

NCT05037487

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Drug Abuse records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Buprenorphine Sublingual Product Drug
3 trials
Buprenorphine Injection Drug
3 trials
Services remain dispersed; i.e., not centralized to one-location or provider. Other
1 trials
Services will be provided at one site Other
1 trials
Integrated Family and Cognitive-Behavioral Therapy Behavioral
1 trials
booster sessions Behavioral
1 trials
referral Behavioral
1 trials
screening Behavioral
1 trials

US sites by state

Facility locations filed on Drug Abuse trials. A trial with sites in several states counts in each.

Massachusetts 6 trials
Washington 5 trials
West Virginia 4 trials
Utah 4 trials
South Carolina 4 trials
New Mexico 4 trials
Florida 4 trials
California 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Drug Abuse page

22 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Drug Abuse condition card totals 22 registered trials; most-linked intervention Buprenorphine Sublingual Product; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.